Therapeutic implications of tocilizumab, a humanized anti-interleukin-6 receptor antibody, for various immune-mediated diseases: An update review

Current Rheumatology Reviews

Volumn 8, Issue 3, 2012, Pages 209-226

  Tanaka, Toshio ^a,b   Ogata, Atsushi ^a   Shima, Yoshihito ^a   Narazaki, Masashi ^a   Kumanogoh, Atsushi ^a   Kishimoto, Tadamitsu ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti interleukin 6 receptor antibody; Autoimmunity; Biologics; Inflammation; Interleukin 6; Tocilizumab

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; CORTICOSTEROID; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 6; METHOTREXATE; PLACEBO; RITUXIMAB; TACROLIMUS; TOCILIZUMAB;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT ONSET STILL DISEASE; AMYLOIDOSIS; ANAPHYLACTOID PURPURA; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; AORTA ARCH SYNDROME; ARTICLE; ATOPIC DERMATITIS; AUTOIMMUNE HEMOLYTIC ANEMIA; BEHCET DISEASE; CHURG STRAUSS SYNDROME; CROHN DISEASE; CRYOGLOBULINEMIA; DISEASE ACTIVITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FRAGILITY FRACTURE; GIANT CELL ARTERITIS; HEMOPHILIA A; HUMAN; HYPERTENSION; IMMUNOPATHOLOGY; ISCHIALGIA; JUVENILE RHEUMATOID ARTHRITIS; LEUKOCYTOCLASTIC VASCULITIS; LOW DRUG DOSE; MONOTHERAPY; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; OSTEOPOROSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PLEIOTROPY; POLYARTERITIS NODOSA; POLYMYOSITIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSING POLYCHONDRITIS; REMISSION; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SPONDYLARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; UVEITIS; WEGENER GRANULOMATOSIS;

EID: 84873171130     PISSN: 15733971     EISSN: 18756360     Source Type: Journal    
DOI: 10.2174/157339710803140210193939     Document Type: Article

References (329)

1. Hirano T, Yasukawa K, Harada H, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986; 324: 73-76.
2. Kishimoto T. The biology of interleukin-6. Blood 1989; 74: 1-10.
3. Kishimoto T. Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol 2005; 23:1-21.
4. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20:197-216.
5. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011; 34:637-650.
6. Matzinger P. The danger model:a renewed sense of self. Science 2002; 296: 301-305.
7. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993; 54:1-78.
8. Akira S, Kishimoto T. IL-6 and NF-IL6 in acute-phase response and viral infection. Immunol Rev 1992; 127: 25-50.
9. Tanaka T, Katada Y, Suemura M, Kishimoto T. Interleukin-6. In: Snapper CM, Ed. Cytokine regulation of humoral immunity: basic and clinical aspects. New Jersey: John Wiley & Sons Ltd. 1996; pp. 251-272.
10. Dinarello CA. Review: infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. J Endotoxin Res 2004; 10: 201-222.
11. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 265: 621-636.
12. Siewert E, Bort R, Kluge R, Heinrich PC, Castell J, Jover R. Hepatic cytochrome p450 down-regulation during aseptic inflammation in the mouse is interleukin 6 dependent. Hepatology 2000; 32: 49-55.
13. Nishikawa T, Hagihara K, Serada S, et al. Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1alpha is essential for cytokine-driven C-reactive protein gene expression. J Immunol 2008; 180: 3492-3501.
14. Hagihara K, Nishikawa T, Isobe T, et al. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Bio-chem Biophys Res Commun 2004; 314: 363-369.
15. Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001; 358: 24-29.
16. Obici L, Perfetti V, Palladini G, Moratti R, Merlini G. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta 2005; 1753: 11-22.
17. Rooney MM, Parise LV, Lord ST. Dissecting clot retraction and platelet aggregation. Clot retraction does not require an intact fi-brinogen gamma chain C terminus. J Biol Chem 1995; 271: 8553-8555.
18. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113: 1271-1276.
19. Kishimoto T. Factors affecting B cell growth and differentiation. Annu Rev Immunol 1985; 3: 133-157.
20. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol 2009; 27: 485-517.
21. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol 2010; 40: 1830-1835.
22. Nurieva RI, Chung Y, Hwang D, et al. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity 2008; 29: 138-149.
23. Okada M, Kitahara M, Kishimoto S, Matsuda T, Hirano T, Kishi-moto T. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol 1988; 141: 1543-1549.
24. Kaplanski G, Marin V, Montero-Julian F, Mantovani A, Farnarier C. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol 2003; 24: 25-29.
25. Chomarat P, Banchereau J, Davoust J, Palucka AK. IL-6 switches the differentiation of monocytes from dendritic cells to macro-phages. Nat Immunol 2000; 1: 510-514.
26. Romano M, Sironi M, Toniatti C, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997; 6: 315-325.
27. Ishibashi T, Kimura H, Shikama Y, et al. Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood 1989; 74: 1241-1244.
28. Kotake S, Sato K, Kim KJ, et al. Interleukin-6 and soluble inter-leukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996; 11: 88-95.
29. Palmqvist P, Persson E, Conaway HH, Lerner UH. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappaB ligand, osteoprotegerin, and receptor activation of NF-kappaB in mouse calvariae. J Immunol 2002; 169: 3353-3362.
30. Nakahara H, Song J, Sugimoto M, et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 2003; 48: 1521-1529.
31. Grossman RM, Krueger J, Yourish D, et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA 1989; 86: 6367-6371.
32. Horii Y, Muraguchi A, Iwano M, et al. Involvement of IL-6 in mesangial proliferative glomerulonephritis. J Immunol 1989; 143: 3945-3955.
33. Duncan MR, Berman B. Stimulation of collagen and glycosamino-glycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol 1991; 97: 686-692.
34. Yamasaki K, Taga T, Hirata Y, et al. Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science 1988; 241: 825-828.
35. Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011; 121: 3375-3383.
36. Hibi M, Murakami M, Saito M, et al. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 1990; 63: 1149-1157.
37. Murakami M, Hibi M, Nakagawa N, et al. IL-6-induced homodi-merization of gp130 and associated activation of a tyrosine kinase. Science 1993; 260: 1808-1810.
38. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science 2003; 300: 2101-2104.
39. Chebath J, Fischer D, Kumar A, et al. Interleukin-6 receptor-interleukin-6 fusion proteins with enhanced interleukin-6 type plei-otropic activities. Eur Cytokine Netw 1997; 8: 359-365.
40. Kishimoto T, Akira S, Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science 1992; 258: 593-597.
41. Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cyto-kines. Annu Rev Immunol 1997; 15: 797-819.
42. Pflanz S, Hibbert L, Mattson J, et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol 2004; 172: 2225-2231.
43. Naka T, Narazaki M, Hirata M, et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997; 387: 924-929.
44. Hirano T, Taga T, Yasukawa K, et al. Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proc Natl Acad Sci USA 1987; 84: 228-231.
45. Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989; 74: 1360-1367.
46. Hirano T, Matsuda T, Turner M, et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 1988; 18: 1797-1801.
47. Matsusaka T, Fujikawa K, Nishio Y, et al. Transcription factors NF-IL6 and NF-κB synergistic activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci USA 1993; 90: 10193-10197.
48. Hao S, Baltimore D. The stability of mRNA influences the temporal order of the induction of genes encoding inflammatory molecules. Nat Immunol 2009; 10: 281-288.
49. Aoki Y, Narazaki M, Kishimoto T, Tosato G. Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpes virus. Blood 2001; 98: 3042-3049.
50. Kang JG, Pripuzova N, Majerciak V, Kruhlak M, Le SY, Zheng ZM. Kaposi's sarcoma-associated herpesvirus ORF57 promotes escape of viral and human interleukin-6 from microRNA-mediated suppression. J Virol 2011; 85: 2620-2630.
51. Qin Z, Keamey P, Plaisance K, Parsons CH. Pivotal advance: Ka-posi's sarcoma-associated herpesvirus (KSHV)-encoded mi-croRNA specifically induce IL-6 and IL-10 secretion by macro-phages and monocytes. J Leukoc Biol 2010; 87: 25-34.
52. Leung K, Nabel GJ. HTLV-1 transactivator induces interleukin-2 receptor expression through an NF-kappa B-like factor. Nature 1988; 333: 776-778.
53. Ballard DW, Bohnlein E, Lowenthal JW, Wano Y, Franza BR, Greene WC. HTLV-1 tax induces cellular proteins that activate the kappa B element in the IL-2 receptor alpha gene. Science 1988; 241: 1652-1655.
54. Scala G, Ruocco MR, Ambrosino C, et al. The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein. J Exp Med 1994; 179: 961-971.
55. Ambrosino C, Ruocco MR, Chen X, et al. HIV-1 Tat induces the expression of the interleukin-6 (IL6) gene by binding to the IL6 leader RNA and by interacting with CAAT enhancer-binding protein beta (NF-IL6) transcription factors. J Biol Chem 1997; 272: 14883-14892.
56. Mahe Y, Mukaida N, Kuno K, et al. Hepatitis B virus X protein transactivates human interleukin-8 gene through acting on nuclear factor kB and CCAAT /enhancer-binding protein-like cis-elements. J Biol Chem 1991; 266: 13759-13763.
57. Ohno H, Kaneko S, Lin Y, Kobayashi K, Murakami S. Human hepatitis B virus X protein augments the DNA binding of nuclear factor for IL-6 through its basic-leucine zipper domain. J Med Virol 1999; 58: 11-18.
58. Tanaka T, Ogata A, Narazaki M. Tocilizumab for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 2010; 6: 843-854.
59. Tanaka T, Kishimoto T. Immunotherapy of tocilizumab for rheumatoid arthritis. J Clin Cell Immunol 2011: S6-S7.
60. Ogata A, Hirano T, Hishitani Y, Tanaka T. Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord 2012; 5: 27-42.
61. Tanaka T, Narazaki M, Kishimoto T. Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol 2012; 52: 199-219.
62. Tanaka T, Kishimoto T. Immunotherapeutic implication of IL-6 blockade. Immunotherapy 2012; 4: 87-105.
63. Klein B, Wijdenes J, Zhang XG, et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991; 78: 1198-1204.
64. Lu ZY, Brochier J, Wijdenes J, Brailly H, Bataille R, Klien B. High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in hman in vivo. Eur J Immunol 1992; 22: 2819-2824.
65. Bataille R, Barlogie B, Lu ZY, et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995; 86: 685-691.
66. Sato K, Tsuchiya M, Saldanha J, et al. Reshaping a human antibody to inhibit the interleukin-6 dependent tumor cell growth. Cancer Res 1993; 53: 851-856.
67. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum in-terleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008; 112: 3959-3964.
68. Tanaka T, Hagihara K, Hishitani Y, Ogata A. Tocilizumab for the treatment of AA amyloidosis. In: Guvenc IA, Ed. Amyloidosis -An insight to disease of systems and novel therapies. Croatia: IN-TECH Open Access Publisher. 2011; pp. 155-170.
69. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007; 370: 1861-1874.
70. Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988; 31: 784-788.
71. Robak T, Gladalska A, Stepien H, et al. Serum levels of interleu-kin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediators Inflamm 1998; 7: 347-353.
72. Holt I, Cooper RG, Hopkins SJ. Relationship between local inflammation, interleukin-6 concentration and the acute phase protein response in arthritis patients. Eur J Clin Invest 1991; 21: 479-484.
73. Dasgupta B, Corkill M, Kirkham B, Gibson T, Panayi G. Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol 1992; 19: 22-25.
74. Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 1993; 52: 232-234.
75. Pascula M, Nieto A, Mataran L, Balsa A, Pascual-Salcedo D, Martin J. IL-6 promoter polymorphisms in rheumatoid arthritis. Genes Immun 2000; 1: 338-340.
76. Lee YH, Bae SC, Choi SJ, Ji JD, Song GG. The association between interleukin-6 polymorphisms and rheumatoid arthritis: a meta-analysis. Inflamm Res 2012; 61: 665-671.
77. Marinou I, Healy J, Mewar D, et al. Association of interleukin-6 and interleukin-10 genotypes with radiographic damage in rheumatoid arthritis is dependent on autoantibody status. Arthritis Rheum 2007; 56: 2549-2556.
78. Pawlik A, Wrzesniewska J, Florczak M, Gawronska-Szklarz B, Herczynska M. IL-6 promoter polymorphism in patients with rheumatoid arthritis. Scand J Rheumatol 2005; 34: 109-113.
79. Kim LH, Lee HS, Kim YJ, et al. Identification of novel SNPs in the interleukin 6 receptor gene (IL-6R). Hum Mutat 2003; 21: 450-451.
80. Galicia JC, Tai H, Komatsu Y, Shimada Y, Akazawa K, Yoshie H. Polymorphisms in the IL-6 receptor (IL-6R) gene: strong evidence that serum levels of soluble IL-6R are genetically influenced. Genes Immun 2004; 5: 513-516.
81. Rafiq S, Frayling TM, Murray A, et al. A common variant of the interleukin 6 receptor (IL-6R) gene increases IL-6R and IL-6 levels, without other inflammatory effects. Genes Immun 2007; 8: 552-559.
82. Rodriguez-Rodriguez L, Lamas JR, Varade J, et al. Plasma soluble IL-6 receptor concentration in rheumatoid arthritis: associations with the rs8192284 IL-6R polymorphism and with disease activity. Rheumatol Int 2011; 31: 409-413.
83. Marinou I, Walters K, Winfield J, Bax DE, Wilson AG. A gain of function polymorphism in the interleukin 6 receptor influences RA susceptibility. Ann Rheum Dis 2010; 69: 1191-1194.
84. Alonzi T, Fattori E, Lazzaro D, et al. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 1998; 187: 461-468
85. Sasai M, Saeki Y, Ohshima S, et al. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum 1999; 42: 1635-1643.
86. Kagari T, Doi H, Shimozato T. The importance of IL-1 beta and TNF-alpha, and the noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis. J Immunol 2002; 169: 1459-1466.
87. Iwakura Y, Nakae S, Saijo S, Ishigame H. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev 2008; 226: 57-79.
88. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab mono-therapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010; 69: 88-96.
89. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomized trial. Lancet 2008; 371: 987-997.
90. Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocili-zumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011; 63: 609-621.
91. Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009; 19: 12-19.
92. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with TCZ reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the TCZ in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58: 2968-2980.
93. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x-ray reader-blinded randomized controlled trial of tocili-zumab. Ann Rheum Dis 2007; 66: 1162-1167.
94. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with TCZ improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicentre randomized placebo controlled trial. Ann Rheum Dis 2008; 67: 1516-1523.
95. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-681.
96. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26-37.
97. Keystone EC, Genovese MC, Klareskog L, et al. GO-FORWARD Study. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009; 68: 789-796.
98. Maini RN, Taylor PC, Szechinski J, et al. CHARISMA Study Group. Double-blind randomized controlled clinical trial of the in-terleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006; 54: 2817-2829.
99. Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2012 May 5. [Epub ahead of print].
100. Ostor A, Romnn Ivorra JA, Wollenhaupt J, et al. Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. Presented at EULAR 2012. Berlin. Abstract FRI0179
101. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009; 68: 1580-1584.
102. Leffers HC, Ostergaard M, Glintborg B, et al. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis 2011; 70: 1216-1222.
103. Hetland ML, Christensen IJ, Tarp U, et al. All Departments of Rheumatology in Denmark. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or in-fliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010; 62: 22-32.
104. N And Japanese MRA study group for RA. Drug free remission after cessation of actemra monotherapy (DREAM Study). Presented at EULAR 2010. Roma. Abstract OP0134
105. N And Japanese MRA study group for RA. Retreatment efficacy and safety to Tocilizumab in patients with rheumatoid arthritis at recurrence (RESTORE study). Presented at EULAR 2010. Roma. Abstract SAT0150
106. Turkstra E, Ng SK, Scuffham PA. A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis. Curr Med Res Opin 2011; 27: 1885-1897.
107. Salliot C, Finckh A, Katchamart W, et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 2011; 70: 266-271.
108. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biol-ogics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011; (2): CD008794.
109. Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab (TCZ) monotherapy is superior to adalimumab (ADA) monotherapy in reducing disease activity in patients with rheumatoid arthritis (RA): 24-week data from the phase 4 ADACTA trial. Presented at EU-LAR 2012. Berlin. Abstract LB0003.
110. Schiff M, Pritchard C, Huffstutter JE, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis 2009; 68: 1708-1714.
111. Tanaka Y. Postmarketing surveillance of abatacept for rheumatoid arthritis in Japan: interim analysis of 1000 patients. presented at JCR (Annual general assembly and scientific meeting of the Japan college of rheumatology) 2012. Tokyo, Japan. Abstract (Japanese).
112. Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum 2010; 39: 425-441.
113. A, And the MUSASHI Study Group. The MUSASHI Study: Comparison of subcutaneous tocilizumab monotherapy versus intravenous tocilizumab monotherapy: Results from a double-blind, parallel-group, comparative phase III non-inferiority study in Japanese patients with rheumatoid arthritis. Presented at EULAR 2012. Berlin. Abstract LB0003.
114. Ruiz-Irastorza G, Khamashta MA, Castellino G, Hughes GR. Systemic lupus erythematosus. Lancet 2001; 357: 1027-1032.
115. Munoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M. The role of defective clearance of apoptotic cells in systemic autoim-munity. Nat Rev Rheumatol 2010; 6: 280-289.
116. Obermoser G, Pascual V. The interferon-α signature of systemic lupus erythematosus. Lupus 2010; 19: 1012-1019.
117. Shin MS, Lee N, Kang I. Effector T-cell subsets in systemic lupus erythematosus: update focusing on Th17 cells. Curr Opin Rheuma-tol 2011; 23: 444-448.
118. Vogt B, Fuhrnrohr B, Muller R, Sheriff A. CRP and the disposal of dying cells: consequences for systemic lupus erythematosus and rheumatoid arthritis. Autoimmunity 2007; 40: 295-298.
119. Rhodes B, Furnrohr BG, Vyse TJ. C-reactive protein in rheumatology: biology and genetics. Nat Rev Rheumatol 2011; 7: 282-289.
120. Tackey E, Lipsky PE, Illei GG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 2004; 13: 339-343.
121. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus: a putative role in pathogenesis. J Immunol 1991; 147: 117-123.
122. Peterson E, Robertson AD, Emlen W. Serum and urinary interleu-kin-6 in systemic lupus erythematosus. Lupus 1996; 5: 571-575.
123. Grondal G, Gunnarsson I, Ronnelid J, Rogberg S, Klareskog L, Lundberg I. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 2000; 18: 565-570.
124. Iwano M, Dohi K, Hirata E, et al. Urinary levels of IL-6 in patients with active lupus nephritis. Clin Nephrol 1993; 40: 16-21.
125. Hirohata S, Miyamoto T. Elevated levels of interleukin-6 in cere-brospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum 1990; 33: 644-649.
126. Hagiwara E, Gourley MF, Lee S, Klinman DK. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10:interferon-gamma-secreting cells in the peripheral blood. Arthritis Rheum 1996; 39: 379-385.
127. Klashman DJ, Martin RA, Martinez-Maza O, Stevens RH. In vitro regulation of B cell differentiation by interleukin-6 and soluble CD23 in systemic lupus erythematosus B cell subpopulations and antigen-induced normal B cells. Arthritis Rheum 1991; 34: 276-286.
128. Kitani A, Hara M, Hirose T, et al. Autostimulatory effects of IL-6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and IL-6R expression. Clin Exp Immunol 1992; 88: 75-83.
129. Lee YH, Lee HS, Choi SJ, Ji JD, Song GG. The association between interleukin-6 polymorphisms and systemic lupus erythema-tosus: a meta-analysis. Lupus 2012; 21: 60-67.
130. Ryffel B, Car BD, Gunn H, Roman D, Hiestand P, Mihatsch MJ. Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice. Am J Pathol 1994; 144: 927-937.
131. Finck BK, Chan B, Wofsy D. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest 1994; 94: 585-591.
132. Mihara M, Takagi N, Takeda Y, Ohsugi Y. IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin Exp Immunol 1998; 112: 397-402.
133. Liang B, Gardner DB, Griswold DE, Bugelski PJ, Song XY. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 2006; 119: 296-305.
134. Pflegerl P, Vesely P, Hantusch B, et al. Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling. Proc Natl Acad Sci USA 2009; 106: 20423-20428.
135. Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010; 62: 542-552.
136. Maeshima K, Ishii K, Torigoe M, et al. Successful tocilizumab and tacrolimus treatment in a patient with rheumatoid arthritis complicated by systemic lupus erythematosus. Lupus 2012; March 20. [Epub ahead of print].
137. Makol A, Gibson LE, Michet CJ. Successful use of interleukin 6 antagonist tocilizumab in a patient with refractory cutaneous lupus and urticarial vasculitis. J Clin Rheumatol 2012; 18: 92-95.
138. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009; 360: 1989-2003.
139. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1998; 15: 202-205.
140. Catoggio LJ, Bernstein RM, Black CM, Hughes GR, Maddison PJ. Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis 1983; 42: 23-27.
141. Hasegawa M, Takehara K. Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines. Semin Arthritis Rheum 2012; April 25. [Epub ahead of print].
142. Barnes TC, Anderson ME, Moots RJ. The many faces of interleu-kin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. Int J Rheumatol 2011:2011:721608.
143. Stuart RA, Littlewood AJ, Maddison PJ, Hall ND. Elevated serum interleukin-6 levels associated with active disease in systemic connective tissue disorders. Clin Exp Rheumatol 1995; 13: 17-22.
144. Hasegawa M, Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol 1998; 25: 308-313.
145. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001; 27: 140-146.
146. Gourh P, Arnett FC, Assassi S, et al. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestation. Arthritis Res Ther 2009; 11: R147.
147. Radstake TR, van Bon L, Broen J, et al. The pronounced Th17 profiles in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotype. Plos One 2009; 4: e5903.
148. Khan K, Xu S, Nihtyanova S, et al. Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann Rheum Dis 2012; May 14. [Epub ahead of print].
149. Feghali CA, Bost KL, Boulware DW, Levy LS. Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma. J Rheumatol 1992; 19: 1207-1211.
150. Koch AE, Kronfeld-Harrington LB, Szekanecz Z, et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis: their role in early and late disease. Pathobiology 1993; 61: 239-246.
151. Gurram M, Pahwa S, Frieri M. Augmented interleukin-6 secretion in collagen-stimulated peripheral blood mononuclear cells from patients with systemic sclerosis. Ann Allergy 1994; 73: 493-496.
152. Giacomelli R, Cipriani P, Danese C, et al. Peripheral blood mono-nuclear cells of patients with systemic sclerosis produce increased amounts of interleukin 6, but not transforming growth factor 1. J Rheumatol 1996; 23: 291-296.
153. Crestani B, Seta N, De Bandt M, et al. Interleukin 6 secretion by monocytes and alveolar macrophages in systemic sclerosis with lung involvement. Am J Respir Crit Care Med 1994; 149: 1260-1265.
154. Scala E, Pallotta S, Frezzolini A, et al. Cytokine and chemokine levels in systemic sclerosis: relation with cutaneous and internal organ involvement. Clin Exp Immunol 2004; 138: 540-546.
155. Gallucci RM, Lee EG, Tomasek JJ. IL-6 modulates alpha-smooth muscle actin expression in dermal fibroblasts from IL-6-deficient mice. J Invest Dermatol 2006; 126: 561-568.
156. Kawaguchi Y, Hara M, Wright TM. Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest 1999; 102: 1253-1260.
157. Barnes TC, Spiller DG, Anderson ME, Edwards SW, Moots RJ. Endothelial activation and apoptosis mediated by neutrophil-dependent interleukin 6 trans-signalling: a novel target for systemic sclerosis? Ann Rheum Dis 2011; 70: 368-372.
158. Sfrent-Cornateanu R, Mihai C, Balan S, Ionescu R, Moldoveanu E. The IL-6 promoter polymorphism is associated with disease activity and disability in systemic sclerosis. J Cell Mol Med 2006; 10: 955-959.
159. Beretta L, Santaniello A, Cappiello F, Barili M, Scorza R. No evidence for a role of the proximal IL-6 G/C -174 single nucleotide polymorphism in Italian patients with systemic sclerosis. J Cell Mol Med 2007; 11: 896-898.
160. Saito E, Fujimoto M, Hasegawa M, et al. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmu-nity in the tight-skin mouse. J Clin Invest 2002; 109: 1453-1462.
161. Matsushita T, Fujimoto M, Hasegawa M, et al. BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice. J Invest Dermatol 2007; 127: 2772-2780.
162. Yoshizaki A, Yanaba K, Ogawa A, Asano Y, Kadono T, Sato S. Immunization with DNA topoisomerase I and Freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via inter-leukin-6 signaling. Arthritis Rheum 2011; 63: 3575-3585.
163. Kitaba S, Murota H, Terao M, et al. Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol 2012; 80: 165-176.
164. Shima Y, Kuwahara Y, Murota H, et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford) 2010; 49: 2408-2412.
165. Kuwahara Y, Shima Y, Shirayama D, et al. Quantification of hardness, elastic and viscosity of the skin of patients with systemic sclerosis using a novel sensing device (Vesmeter): a proposal for a new outcome measurement procedure. Rheumatology (Oxford) 2008; 47: 1018-1024.
166. Dalakas MC. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol 2010; 6: 129-137.
167. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev 2008; 88: 1379-1406.
168. Carson JA, Baltgalvis KA. Interleukin-6 as a key regulator of muscle mass during cachexia. Exerc Sport Sci Rev 2010; 38: 168-176.
169. Gabay C, Gay-Croisier F, Roux-Lombard P, et al. Elevated serum levels of interleukin-1 receptor antagonist in polymyosi-tis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response. Arthritis Rheum 1994; 37: 1744-1751.
170. Lundberg I, Ulfgren AK, Nyberg P, Andersson U, Klareskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997; 40: 865-874.
171. Lepidi H, Frances V, Figarella-Branger D, Bartoli C, Machado-Baeta A, Pellissier JF. Local expression of cytokines in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 1998; 24: 73-79.
172. Scuderi F, Mannella F, Marino M, Provenzano C, Bartoccioni E. IL-6-deficient mice show impaired inflammatory response in a model of myosin-induced experimental myositis. J Neuroimmunol 2006; 176: 9-15.
173. Okiyama N, Sugihara T, Iwakura Y, Yokozeki H, Miyasaka N, Kohsaka H. Therapeutic effects of interleukin-6 blockade in a mur-ine model of polymyositis that does not require interleukin-17A. Arthritis Rheum 2009; 60: 2505-2512.
174. Narazaki M, Hagihara K, Shima Y, Ogata A, Kishimoto T, Tanaka T. Therapeutic effect of tocilizumab on two patients with polymy-ositis. Rheumatology (Oxford) 2011; 50: 1344-1346.
175. Langford CA. Vasculitis. J Allergy Clin Immunol 2010; 125: S216-S225.
176. Sharma P, Sharma S, Baltaro R, Hurley J. Systemic vascultis. Am Fam Physician 2011; 83: 556-565.
177. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitdes. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-192.
178. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008; 372: 234-245.
179. Mason JC. Takayasu arteritis-advances in diagnosis and management. Nat Rev Rheumatol 2010; 6: 405-415.
180. Noris M, Daina E, Gamba S, Bonazzola S, Remuzzi G. Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions? Circulation 1999; 100: 55-60.
181. Park MC, Lee SW, Park YB, Lee SK. Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology (Oxford) 2006; 45: 545-548.
182. Dasgupta B, Panayi GS. Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol 1990; 29: 456-458.
183. Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 1993; 36: 1286-1294.
184. Caplanne D, Le Parc JM, Alexandre JA. Interleukin-6 in clinical relapses of polymyalgia and giant cell arteritis. Ann Rheum Dis 1996; 55: 403-404.
185. Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum. 2000; 43: 1041-1048.
186. Garcia-Martinez A, Hernandez-Rodriguez J, Espigol-Frigole G, et al. Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term fol-lowup of patients with giant cell arteritis. Arthritis Care Res (Hoboken) 2010; 62: 835-841.
187. Wagner AD, Goronzy JJ, Weyand CM. Functional profile of tissue-infiltrating and circulating CD68+ cells in giant cell arteritis. Evidence for two components of the disease. J Clin Invest 1994; 94: 1134-1140.
188. Weyand CM, Hicok KC, Hunder GG, Goronzy JJ. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell ar-teritis. Ann Intern Med 1994; 121: 484-491.
189. Hernandez-Rodriguez J, Segarra M, Vilardell C, et al. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford) 2004; 43: 294-301.
190. Seko Y, Sato O, Takagi A, et al. Restricted usage of T-cell receptor Valpha-Vbeta genes in infiltrating cells in aortic tissue of patients with Takayasu's arteritis. Circulation 1996; 93: 1788-1790.
191. Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 2010; 121: 906-915.
192. Arnaud L, Haroche J, Mathian A, Gorochov G, Amoura Z. Patho-genesis of Takayasu's arteritis: a 2011 update. Autoimmun Rev 2011; 11: 61-67.
193. Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 2008; 58, 1197-1200.
194. Seitz M, Reichenbach S, Bonel HM, Adler S, Wermelinger F, Villiger PM. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 2011; 141: w13156.
195. Beyer C, Axmann R, Sahinbegovic E, et al. Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis. Ann Rheum Dis 2011; 70: 1874-1875.
196. Sciascia S, Rossi D, Roccatello D. Interleukin 6 blockade as steroid-sparing treatment for 2 patients with giant cell arteritis. J Rheumatol 2011; 38: 2080-2081.
197. Salvarani C, Magnani L, Catanoso M, et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (0xford) 2012; 51: 151-156.
198. Vinit J, Bielefeld P, Muller G, Besancenot JF. Efficacy of tocilizu-mab in refractory giant cell arteritis. Joint Bone Spine 2012; 79: 317-318.
199. Christidis D, Jain S, Das Gupta B. Successful use of tocilizumab in polymyalgic onset biopsy positive GCA with large vessel involvement. BMJ Case Reports 2011; Aug 17. [Epub ahead of print].
200. Besada E, Nossent JC. Ultrasonographic resolution of the vessel wall oedema with modest clinical improvement in a large-vessel vasculitis patient treated with tocilizumab. Clin Rheumatol 2012; Jun 2. [Epub ahead of print].
201. Salvarani C, Magnani L, Catanoso MG, et al. Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-α blockers. Clin Exp Rheumatol 2012; Feb 27. [Epub ahead of print].
202. Bredemeier M, Rocha CM, Barbosa MV, et al. One-year clinical and radiological evolution of a patient with refractory Takayasu's arteritis under treatment with tocilizumab. Clin Exp Rheumatol 2012; Feb 27. [Epub ahead of print].
203. Unizony S, Arias-Urdaneta L, Miloslavsky E, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Ta-kayasu arteritis) and polymyalgia rheumatica. Arthritis Res Care (Hoboken) 2012; Jun 5. [Epub ahead of print].
204. Cid MC, Hernandez-Rodriquez J, Esteban MJ, et al. Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arthritis. Circulation 2002; 106: 1664-1671.
205. Hernandez-Rodriquez J, Segarra M, Vilardell C, et al. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 2003; 107: 2428-2434.
206. Muller Kobold AC, van Wijk RT, Franssen CF, et al. In vitro up-regulation of E-selectin and induction of interleukin-6 in endothelial cells by autoantibodies in Wegener's granulomatosis and microscopic polyangitis. Clin Exp Rheumatol 1999; 17: 433-440.
207. Popa ER, Franssen CF, Limburg PC, Huitema MG, Kallenberg CG, Tervaert JW. In vitro cytokine production and proliferation of T cells from patients with anti-proteinase 3- and antimyeloperoxi-dase-associated vasculitis, in response to proteinase 3 and myelop-eroxidase. Arthritis Rheum 2002; 46: 1894-1904.
208. Ohlsson S, Bakoush O, Tencer J, Torffvit O, Segelmark M. Mono-cyte chemoattractant protein 1 is a prognostic marker in ANCA-associated small vessel vasculitis. Mediators Inflamm 2009; 584916.
209. Antonelli A, Ferri C, Ferrari SM, et al. Serum levels of proinflam-matory cytokines interleukin-1beta, interleukin-6, and tumor necrosis factor alpha in mixed cryoglobulinemia. Arthritis Rheum 2009; 60: 3841-3847.
210. Besbas N, Saatci U, Ruacan S, et al. The role of cytokines in He-noch Schonlein purpura. Scand J Rheumatol 1997; 26: 456-460.
211. Nakahama H, Okada M, Miyazaki M, Imai N, Yokokawa T, Kubori S. Distinct responses of interleukin-6 and other laboratory parameters to treatment in a patient with polyarteritis nodosa: a case report. Angiology 1992; 43: 512-516.
212. Lin CY, Lin CC, Hwang B, Chiang B. Serial changes of serum interleukin-6, interleukin-8, and tumor necrosis factor alpha among patients with Kawasaki diseases. J Pediatr 1992; 121: 924-926.
213. Lin CY, Lin CC, Hwang B, Chaing B. Cytokines predict coronary aneurysm formation in Kawasaki disease. Eur J Pediatr 1993; 152: 309-312.
214. Cohen C, Mekinian A, Saidenberg-Kermanach N, et al. Efficacy of tocilizumab in rituximab-refractory cryoglobulinemia vasculitis. Ann Rheum Dis 2012; 71: 628-629.
215. Sumida K, Ubara Y, Suwabe T, et al. Complete remission of mye-loperoxidase-antineutrophil cytoplasmic antibody-associated cres-centic glomerulonephritis complicated with rheumatoid arthritis using a humanized anti-interleukin 6 receptor antibody. Rheumatology (0xford) 2011; 50: 1928-1930.
216. Alvarez-Rodriguez L, Lopez-Hoyos M, Mata C, et al. Circulating cytokines in active polymyalgia rheumatica. Ann Rheum Dis 2010; 69: 263-269.
217. Gonzalez-Gay MA, Hajeer AH, Dababneh A, et al. IL-6 promoter polymorphism at position -174 modulates the phenotypic expression of polymyalgia rheumatica in biopsy-proven giant cell arteri-tis. Clin Exp Rheumatol 2002; 20: 179-184.
218. Boiardi L, Casali B, Farnetti E, et al. Relationship between inter-leukin 6 promoter polymorphism at position -174, IL-6 serum levels, and the risk of relapse/recurrence in polymyalgia rheumatica J Rheumatol 2006; 33: 703-708.
219. Gabriel SE, Sunku J, Salvarani C, O'Fallon WM, Hunder GG. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 1997; 40: 1873-1878.
220. Mazzantini M, Torre C, Miccoli M, et al. Adverse events during long term low-dose glucocorticoid treatment of polymyalgia rheu-matica: a retrospective study. J Rheumatol 2012; 39: 552-557.
221. Cimmino MA, Salvarani C, Macchioni P, et al. Long-term follow-up of polymyalgia rheumatica patients treated with methotrexate and steroids. Clin Exp Rheumatol 2008; 26: 395-400.
222. Spies CM, Burmester GR, Buttgereit F. Methotrexate treatment in large vessel vasculitis and polymyalgia rheumatica. Clin Exp Rheumatol 2010; 28(5 Suppl 61): S172-S177.
223. Hagihara K, Kawase I, Tanaka T, Kishimoto T. Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica. J Rheumatol 2010; 37: 1075-1076.
224. McCarty DJ, O'Duffy JD, Pearson L, Hunter JB. Remitting sero-negative symmetrical synovitis with pitting edema. RS3PE syndrome. JAMA 1985; 254: 2763-2767.
225. Sibilia J, Friess S, Schaeverbeke T, et al. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE): a form of para-neoplastic polyarthritis? J Rheumatol 1999; 26: 115-120.
226. Oide T, Ohara S, Oguchi K, et al. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome in Nagano, Japan: clinical, radiological, and cytokine studies of 13 patients. Clin Exp Rheumatol 2004; 22: 91-98.
227. Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis 2005; 64: 1653-1655.
228. Kawashiro S, Nakano M, Kawakami A, et al. Monitoring of therapeutic efficacy in a patient with RS3PE syndromes by serologic and radiographic methods. Rheumatol Int 2010; 30: 1677-1680.
229. Tanaka T, Hagihara K, Shima Y, et al. Treatment of a patient with remitting seronegative, symmetrical synovitis with pitting oedema with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Rheumatology (Oxford) 2010; 49: 824-826.
230. Mendes D, Correia M, Barbedo M, et al. Behcet's disease-a contemporary review. J Autoimmun 2009; 32: 178-188.
231. Hirohata S, Oka H, Mizushima Y. Streptococcal-related antigens stimulate production of IL-6 and interferon-gamma by T cells from patients with Behcet's disease. Cell Immunol 1992; 140: 410-419.
232. Mege JL, Dilsen N, Sanguedolce V, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993; 20: 1544-1549.
233. Kulaber A, Tugal-Tutkun I, Sibel P, et al. Pro-inflammatory cellular immune response in Behcet's disease. Rheumatol Int 2007; 27: 1113-1118.
234. Hirano T, Ohguro N, Hohki S, et al. A case of Behcet's disease treated with a humanized anti-interleukin-6 receptor antibody, to-cilizumab. Mod Rheumatol 2012; 22: 298-302.
235. Hirohata S, Isshi K, Oguchi H, et al. Cerebrospinal fluid interleu-kin-6 in progressive neuro-Behcet's syndrome. Clin Immunol Im-munopathol 1997; 82: 12-17.
236. Akman-Demir G, Tuzun E, Icoz S, et al. Interleukin-6 in neuro-Bechet's disease: association with disease subsets and long-term outcome. Cytokine 2008; 44: 373-376.
237. Borhani Haghighi A, Ittehadi H, Nikseresht AR, et al. CSF levels of cytokines in neuro-Behcet's disease. Clin Neurol Neurosurg 2009; 111: 507-510.
238. Shapiro LS, Farrell J, Haghighi AB. Tocilizumab treatment for nuero-Behcet's disease, the first report. Ocular Immunol Inflamm 2011; 19: 382-383.
239. Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castle-man's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000; 95: 56-61.
240. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005; 106: 2627-2632.
241. Woo P, Wilkinson N, Prieur AM, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 2005; 7: R1281-R1288.
242. Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005; 52: 818-825.
243. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocili-zumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008; 371: 998-1006.
244. De Benedetti F, Brunner H, Ruperto N, et al. Tocilizumab in patients with systemic juvenile idiopathic arthritis: efficacy data from the placebo-controlled 12-week part of the phase 3 TENDER trial. Arthritis Rheum 2010; 62(Suppl 10): 143-144.
245. De Benedetti F, Brunner H, Ruperto N, et al. Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data. Pediat Rheumatol 2011; 9(Suppl 1): 164.
246. Yokota S, Tanaka T, Kishimoto T. Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis. Ther Adv Musculo Dis In press
247. Imagawa T, Yokota S, Mori M, et al. Safety and efficacy of tocili-zumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol 2012; 22: 109-115.
248. Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004; 126, 989-996.
249. Iwamoto M, Nara H, Hirata D, Minota S, Nishimoto N, Yoshizaki K. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum 2002; 46: 3388-3389.
250. Nakahara H, Mima T, Yoshino-Hoshino N, Matsushita M, Hashimoto J, Nishimoto N. A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocili-zumab over 6 years. Mod Rheumatol 2009; 19: 69-72.
251. De Bandt M. Saint-Marcoux B. Tocilizumab for multirefractory adult-onset Still's disease. Ann Rheum Dis 2009; 68: 153-154.
252. Matsumoto K, Nagashima T, Takatori S, et al. Glucocorticoid and cyclosporine refractory adult onset Still's disease successfully treated with tocilizumab. Clin Rheumatol 2009; 28: 485-487.
253. Cunha ML, Wagner J, Osawa A, Scheinberg M. The effect of to-cilizumab on the uptake of 18FDG-PET imaging in patients with adult-onset Still's disease. Rheumatology (Oxford) 2010; 49: 1014-1016.
254. Sumida K, Ubara Y, Hoshino J, et al. Etanercept-refractory adult-onset Still's disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab. Clin Rheumatol 2010; 29: 1191-1194.
255. Yoshimura M, Makiyama J, Koga T, et al. Successful treatment with tocilizumab in a patient with refractory adult-onset Still's disease (AOSD). Clin Exp Rheumatol 2010; 28: 141-142.
256. Perdan-Pirkmajer K, Praprotnik S, Tomsic M. A case of refractory adult-onset Still's disease successfully controlled with tocilizumab and a review of the literature. Clin Rheumatol 2010; 29: 1465-1467.
257. Naniwa T, Ito R, Watanabe M, et al. Case report: successful use of short-term add-on tocilizumab for multirefractory systemic flare of adult-onset Still's disease. Clin Rheumatol 2010; Sep 15. [Epub ahead of print].
258. Kishida D, Okuda Y, Ohnishi M, et al. Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis. Mod Rheumatol 2011; 21: 215-218.
259. Thonhofer R, Hiller M, Just H, Trummer M, Siegel C, Dejaco C. Treatment of refractory adult-onset Still's disease with tocilizumab: report of two cases and review of the literature. Rheumatol Int 2011; 31: 1653-1656.
260. Sabnis GR, Gokhale YA, Kulkarni UP. Tocilizumab in refractory adult-onset Still's disease with aseptic meningitis-efficacy of inter-leukin-6 blockade and review of the literature. Semin Arthritis Rheum 2011; 40: 365-368.
261. Rech J, Ronneberger M, Englbrecht M, et al. Successful treatment of adult-onset Still's disease refractory to TNF and IL-1 blockade by IL-6 blockade. Ann Rheum Dis 2011; 70: 390-392.
262. Kobayashi M, Takahashi Y, Yamashita H, Kaneko H, Mimori A. Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome. Mod Rheumatol 2011; 21: 92-96.
263. Puechal X, DeBandt M, Berthelot JM, et al. Tocilizumab in refractory adult Still's disease. Arthritis Care Res (Hoboken) 2011; 63: 155-159.
264. Sekkach Y, Elqatni M, Khattabi AE, et al. Antagonists of interleu-kin-6 (tocilizumab), in adult refractory still disease. Presse Med 2011; 40: e333-e337.
265. Suematsu R, Ohta A, Matsuura E, et al. Therapeutic response of patients with adult Still's disease to biologic agents: multicenter results in Japan. Mod Rheumatol 2011; Dec 9. [Epub ahead of print].
266. Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum 2006; 54: 2997-3000.
267. Nishida S, Hagihara K, Shima Y, et al. Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment. Ann Rheum Dis 2009; 68: 1235-1236.
268. Sato H, Sakai T, Sugaya T, et al. Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis. Clin Rheumatol 2009; 28: 1113-1116.
269. Inoue D, Arima H, Kawanami C, et al. Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis. Clin Rheumatol 2010; 29: 1195-1197.
270. De La Torre M, Arboleya L, Pozo S, et al. Rapid and sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in a patient with nephritic syndrome secondary to systemic juvenile idiopathic arthritis-related amyloidosis. NDT Plus 2011; 4: 178-180.
271. Magro-Checa C, Navas-Parejo Casado A, Borrego-Garcia E, et al. Successful use of tocilizumab in a patient with nephritic syndrome due to a rapidly progressing AA amyloidosis to latent tuberculosis. Amyloid 2011; 18: 235-9.
272. Hattori Y, Ubara Y, Sumida K, et al. Tocilizumab improves cardiac disease in a hemodialysis patient with AA amyloidosis secondary to rheumatoid arthritis. Amyloid 2012; 19: 37-40.
273. Kawai M, Hagihara K, Hirano T, et al. Sustained response to to-cilizumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis. Rheumatology (Oxford) 2009; 48: 318-319.
274. Narshi CB, Allard SA. Sustained response to tocilizumab, anti-IL-6 antibody, following anti-TNF-α failure in a patient with relapsing polychondritis complicated by aortitis. Rheumatology (Oxford) 2012; 51: 952-953.
275. Nishida S, Kawasaki T, Kashiwagi H, et al. Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with to-cilizumab. Mod Rheumatol 2011; 21: 420-422.
276. Kunitomi A, Konaka Y, Yagita M, Nishimoto N, Kishimoto T, Takatsuki K. Humanized anti-interleukin 6 receptor antibody induced long-term remission in a patient with life-threatening refractory autoimmune hemolytic anemia. Int J Hematol 2004; 80: 246-249.
277. Yuzuriha A, Saitoh T, Koiso H, et al. Successful treatment of autoimmune hemolytic anemia associated with multicentric Castleman disease by anti-interleukin-6 receptor antibody (tocilizumab) therapy. Acta Haematol 2011; 126: 147-150.
278. Garcia-Hernandez FJ, Gonzalez-Leon R, Castillo-Palma MJ, Ocana-Medina C, Sanchez-Roman J. Tocilizumab for treating refractory haemolytic anemia in a patient with systemic lupus erythematosus. Rheumatology (Oxford) 2012; April 17. [Epub ahead of print].
279. Muselier A, Bielefeld P, Bidot S, Vinit J, Besancenot JF, Bron A. Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocular Immunol Inflamm 2011; 19: 382-383.
280. Tappeiner C, Heinz C, Ganser G, Heiligenhaus A. Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol 2002; 39: 1294-1295.
281. Gergis U, Arnason J, Yantiss R, et al. Effectiveness and safety of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in a patient with refractory GI graft-versus-host disease. J Clin Onocol 2010; 28: e602-e604.
282. Drobyski WR, Pasquini M, Kovatovic K, et al. Tocilizumab for the treatment of steroid refractory graft versus host disease. Biol Blood Marrow Transplant 2011; 17: 1862-1868.
283. Vaitla PM, Radford PM, Tighe PJ, et al. Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: Assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Arthritis Rheum 2011; 63: 1151-1155.
284. McDermott MF, Aksentijevick I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97: 133-144.
285. Tanaka T, Kuwahara Y, Shima Y, et al. Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Arthritis Rheum 2009; 61: 1762-1764.
286. Henes JC, Horger M, Guenaydin I, et al. Mixed response to tocili-zumab for ankylosing spondylitis. Ann Rheum Dis 2010; 69: 2217-2218.
287. Wendling D, Bossert M, Prati C. Short-term effect of IL-6 inhibition in spondylarthritis. Joint Bone Spine 2010; 77: 624-625.
288. Brulhart L, Nissen MJ, Chevallier P, Gabay C. Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists. Joint Bone Spine 2010; 77: 625-626.
289. Shima Y, Tomita T, Ishii T, et al. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis. Mod Rheu-matol 2011; 21: 436-439.
290. Cohen JD, Ferreira R, Jorgensen C. Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab. J Rheumatol 2011; 38: 1527.
291. Koumakis E, Feydy A, Kahan A, Allanore Y. Interleukin 6 blockade in spondyloarthritis. J Rheumatol 2012; 39: 1097-1098.
292. Dudler J, Aubry-Rozier B. Tocilizumab in axial spondy-larthropathies: about 18 cases. Ann Rheum Dis 2010; 70: 128.
293. Del Castillo Pinol N, Gossec L, Sparsa L, et al. Tocilizumab for treatment of refractory spondyarthritis: report of 5 patients. Ann Rheum Dis 2011; 70: 343.
294. Ogata A, Umegaki N, Katayama I, Kumanogoh A, Tanaka T. Pso-riatic arthritis in two patients with an inadequate response to treatment with tocilizumab. Joint Bone Spine 2012; 79: 85-87.
295. Taniguchi K, Shimazaki C, Fujimoto Y, et al. Tocilizumab is effective for pulmonary hypertension associated with multicentric Cas-tleman's disease. Int J Hematol 2009; 90: 99-102.
296. Arita Y, Sakata Y, Sudo T, et al. The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Cas-tleman's disease. Heart Vessels 2010; 25: 444-447.
297. Furuya Y, Satoh T, Kuwana M. Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension. Int J Rheumatol 2010; Article ID 720305
298. Navarini AA, French LE, Hofbauer GFL. Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial superinfection. J Allergy Clin Immunol 2011; 128: 1128-1130.
299. Ohtori S, Miyagi M, Eguchi Y, et al. Efficacy of epidural administration of anti-interleukin-6 receptor antibody onto spinal nerve for treatment of sciatica. Eur Spine J 2012; Feb 21. [Epub ahead of print].
300. Pradhan AD, Manson JE, Ritai N, Buring JE, Ricker PM. C-reactive protein, interleukin-6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-334.
301. Feve B, Bastard JP. The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 2009; 5: 305-311.
302. Ellingsgaard H, Hauselmann I, Schuler B, et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 2011; 17: 1481-1489.
303. Ogata A, Morishima A, Hirano T, et al. Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab. Ann Rheum Dis 2011; 70: 1164-1165.
304. Schultz O, Oberhauser F, Saech J, et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One 2010; 5: e14328.
305. Hirao M, Yamasaki N, Oze H, et al. Serum level of oxidative stress marker is dramatically low in patients with rheumatoid arthritis treated with tocilizumab. Rheumatol Int 2011; Sep 11. [Epub ahead of print].
306. Protogerou AD, Zampeli E, Fragiadaki K, Stamatelopoulos K, Papamichael C, Sfikakis PP. A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis. Atherosclerosis 2011; 219: 734-736.
307. Kume K, Amano K, Yamada S, Hatta K, Ohta H, Kuwaba N. To-cilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial. J Rheumatol 2011; 38: 2169-2171.
308. Matthijs Boekholdt S, Stores ESG. The interleukin-6 pathway and atherosclerosis. Lancet 2012, 379: 1176-1178.
309. Hou T, Tieu BC, Ray S, et al. Roles of IL-6-gp130 signaling in vascular inflammation. Curr Cardiol Rev 2008; 4: 179-192.
310. IL-6R Genetics Consortium Emerging Risk Factors Collaboration, Sarwar N, Butterworth AS, Freitag DF, et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012; 379: 1205-1213.
311. The Interleukin-6 Receptor Mendelian Randomization Analysis (IL-6R MR) Consortium, Hingorani AD, Casas JP. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomization analysis. Lancet 2012; 379: 1214-1224.
312. Scheller J, Rose-John S. The interleukin 6 pathway and atherosclerosis. Lancet 2012; 380: 338.
313. Song SN, Tomosugi N, Kawabata H, Ishikawa T, Nishikawa T, Yoshizaki K. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood 2010; 116: 3627-3634.
314. Fujimoto M, Serada S, Mihara M, et al. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum 2008; 58: 3710-3719.
315. Iwanami K, Matsumoto I, Tanaka-Watanabe Y, et al. Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase. Arthritis Rheum 2008; 58: 754-763.
316. Chen X, Das R, Komorowski R, et al. Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood 2009; 114: 891-900.
317. Yoshimura T, Sonoda KH, Ohguro N, et al. Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology (Oxford) 2009; 48: 347-354.
318. Hohki S, Ohguro N, Haruta H, et al. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses. Exp Eye Res 2010; 91: 162-170.
319. Haruta H, Ohguro N, Fujimoto M, et al. Blockade of interleukin-6 signaling suppresses not only Th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 2011; 52: 3264-3271.
320. Serada S, Fujimoto M, Mihara M, et al. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2008; 105: 9041-9046.
321. Doganci A, Eigenbrod T, Krug N, et al. The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. J Clin Invest 2005; 115: 313-325.
322. Samson M, Audia S, Janikashvili N, et al. Inhibition of IL-6 function corrects Th17/Treg imbalance in rheumatoid arthritis patients. Arthritis Rheum 2012; April 5. [Epub ahead of print].
323. Roll P, Muhammad K, Schumann M, et al. In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment. Arthritis Rheum 2011; 63: 1255-1264.
324. Muhammad K, Roll P, Seibold T, et al. Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hy-permutation in preswitch memory B cells and mutational targeting in memory B cells. Ann Rheum Dis 2011; 70: 1507-1510.
325. Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA 2011; 108: 3701-3706.
326. Engel P, Gomez-Puerta JA, Ramos-Casals M, Lozano F, Bosch X. Therapeutic targeting of B cells for rheumatic autoimmune diseases. Pharmacol Rev 2011; 63: 127-156.
327. Yamamura T, Miyake S. B-cell-directed therapy: which B cells should be targeted and how? Immunotherapy 2012; 4: 455-457.
328. Zhao W, Liu M, Kirkwood KL. P38alpha stabilizes interleukin-6 mRNA via multiple AU-rich elements. J Biol Chem 2008; 283: 1778-1785.
329. Iwasaki H, Takeuchi O, Teraguchi S, et al. The IkB kinase complex regulates the stability of cytokine-encoding mRNA induced by TLR-IL-1R by controlling degradation of regnase-1. Nat Immunol 2011; 12: 1167-1175.